Apigenin is a naturally occurring flavonoid concentrated in chamomile tea, parsley, and celery. As interest in plant-based compounds for hormonal support has grown, apigenin has attracted attention for two reasons: it can interact with estrogen receptors in laboratory models, and chamomile, its richest dietary source, has a long history of use in women’s health. For women navigating perimenopause, hormonal questions, or fertility concerns, understanding what apigenin actually does, and what the evidence genuinely supports, matters more than marketing claims.
This article examines current research on apigenin and women’s hormonal biology across three areas: its phytoestrogenic activity at estrogen receptors, human and clinical data on menopause symptom relief, and reproductive considerations drawn largely from animal models. Where findings are preliminary or come only from cell cultures, we say so plainly. Nothing here constitutes medical advice, and these statements have not been evaluated by the FDA.
Key Takeaways
- Apigenin binds estrogen receptor alpha (ERα) in laboratory models and shows potential SERM-like properties in cell studies [1][2], but human hormonal effects at typical doses are not established.
- A 2025 triple-blind trial in 80 postmenopausal women found that chamomile extract capsules (1.2% apigenin) lowered menopause symptom scores more than placebo over 12 weeks, although the placebo group also improved and two women in the chamomile group dropped out after mouth sores, skin spots and itching [3]; the benefit cannot be attributed to apigenin alone [3].
- Preclinical research suggests apigenin may oppose hormone-sensitive cancer cell growth [4][2], but these are cell culture and animal findings, not clinical outcomes.
- Animal data raise theoretical reproductive considerations for phytoestrogens [5]; no human fertility trials on apigenin exist, so women trying to conceive should consult a physician before supplementing.
- Apigenin inhibited CYP2C9 and CYP3A4 in test-tube studies, so interactions with warfarin, statins or hormonal medications are possible but have not been shown in people; physician consultation is sensible [19][20][21].
Apigenin as a Phytoestrogen: What Estrogen Receptor Research Shows
Phytoestrogens are plant-derived compounds that can bind to and activate, or block, estrogen receptors (ERs). Apigenin belongs to this functional category, though its estrogenic potency is generally considered weaker than isoflavones like genistein. Research using cell-based models has investigated whether apigenin behaves as a selective estrogen receptor modulator (SERM), meaning it might activate certain ER-dependent pathways while opposing others, depending on the tissue. A 2017 study assessed apigenin and other major dietary flavonoids for potential SERM-like activity using two distinct cell models for proliferation and differentiation [1]. This type of dual activity is pharmacologically important because genuine SERMs can, in principle, be protective in some tissues while opposing estrogen in others, but whether apigenin achieves this in the human body at dietary or typical supplemental doses has not been established clinically.
More recent work has examined apigenin’s affinity for ESR1, the gene encoding estrogen receptor alpha (ERα), which drives a significant proportion of hormone-sensitive breast cancers. A 2026 integrated computational and cell-based study characterized apigenin as a dual inhibitor of both PARP1 and ESR1 [2]. The demonstrated binding to ERα helps explain both the potential interest in apigenin for hormonal applications and the caution warranted in hormone-sensitive clinical contexts. Importantly, binding affinity in a lab model does not automatically predict benefit or harm in a whole human system: these findings generate hypotheses that human trials would need to confirm.
Menopause Symptom Relief: Chamomile, Apigenin, and the Clinical Evidence
Chamomile (Matricaria chamomilla) is the most concentrated common dietary source of apigenin, and it has a documented history of use for women’s health across many cultures. A 2025 triple-blind clinical trial evaluated the efficacy and safety of a chamomile intervention in managing menopausal symptoms and found a larger fall in the overall menopause symptom score with chamomile extract than with placebo in 80 postmenopausal women over 12 weeks, although the placebo group also improved and two women in the chamomile group dropped out after mouth sores, skin spots and itching [3]. It was a single-centre trial of a chamomile extract capsule, not isolated apigenin, so it is a modest data point rather than proof [3].
Research note: For chamomile extract preparations, the EU herbal monograph says safety during pregnancy and breastfeeding has not been established and use is not recommended for lack of data. The herbal tea preparation is the exception: safety in pregnancy and lactation is stated as established [24].
An important caveat: chamomile contains multiple bioactive compounds beyond apigenin, including α-bisabolol, chamazulene, and various apigenin glycosides. The symptom-relief effects observed in that trial cannot be attributed to apigenin alone. In cell experiments apigenin affected GABA-A receptors, but not through the benzodiazepine site, and an anxiolytic or sleep effect of apigenin itself in people has not been shown, so any contribution to the anxiety and sleep disruption that frequently accompany menopause is a hypothesis that would need targeted research within a whole chamomile preparation [15][16][17][18].
Survey-based research has documented that botanical supplement use is common among peri- and postmenopausal women [6]. This pattern of use reflects real demand for non-pharmaceutical options during hormonal transition, and it underscores why rigorous clinical trials on safety and efficacy matter. Popular use does not equal proven benefit, and interactions with medications commonly prescribed in this age group deserve explicit evaluation.
ER-Alpha vs. ER-Beta: Why the Distinction Matters
Research comparing flavonoid behavior at the two estrogen receptor subtypes has found that phytoestrogens do not activate ERα and ERβ equally. In transfected breast cancer cell models, different phytoestrogens induced differential transcriptional responses depending on which receptor was expressed, with some compounds showing preferential ERβ activity [8]. ERβ preference is considered relevant because ERβ activation has been associated with anti-proliferative signaling in certain tissue contexts, in contrast to the proliferative signaling often associated with ERα stimulation.
Apigenin has been characterized as exhibiting greater relative affinity for ERβ than for ERα. Early work established that phytoestrogens as a class interact with ERβ at concentrations potentially achievable through dietary exposure [9], and subsequent receptor-binding analyses placed apigenin within a group of flavonoids that preferentially engage ERβ-mediated pathways [10]. Whether this preferential ERβ engagement translates into a net protective or stimulatory effect in any given tissue is not yet definitively resolved and depends on local receptor expression levels, co-regulatory proteins, and the surrounding hormonal environment.
Partial Agonist Activity: What In Vivo Evidence Shows
Binding to an estrogen receptor does not automatically produce the same response as estradiol itself. A partial agonist activates a receptor but generates a submaximal signal, and in the presence of a full agonist like estradiol it may compete for the binding site and reduce the net estrogenic response. A 2021 study using in vivo models found that apigenin acts as a partial agonist at estrogen receptors, producing measurable but submaximal estrogenic responses compared to estradiol [11]. This partial agonism profile is central to how apigenin’s effects should be interpreted for women’s health.
For premenopausal women with substantial circulating estradiol, apigenin’s partial agonism could theoretically mean mild modulation of ER signaling that is more competitive with endogenous estrogen than additive to it. For postmenopausal women with very low estradiol, any partial agonism may be more directionally estrogenic because the receptor is less occupied by endogenous ligand. These are theoretically important distinctions, but they have not been worked out in clinical trials evaluating apigenin supplementation in women specifically.
Apigenin and Aromatase: A Complex and Honest Picture
Beyond direct receptor binding, apigenin has been studied for its effects on aromatase (CYP19), the enzyme responsible for converting androgens into estrogens. A landmark 1984 study published in Science demonstrated that flavones, a class that includes apigenin, inhibit human estrogen synthetase (aromatase) in vitro, suggesting a possible mechanism by which dietary flavones could reduce endogenous estrogen production [12]. This finding generated sustained research interest, particularly in relation to conditions where reducing estrogenic signaling is a therapeutic consideration.
Subsequent work has considerably complicated this picture. Studies using H295R adrenocortical carcinoma cells found that flavonoid compounds can both inhibit and induce aromatase activity in a concentration-dependent and structure-dependent manner [13], making simple extrapolation from a single inhibition finding to clinical outcomes unreliable. More critically, a study specifically examining whether aromatase-inhibiting flavonoids produce detectable effects in living organisms found no evidence that dietary or supplemental flavonoids meaningfully suppress aromatase activity in vivo [14]. This gap between in vitro inhibition and in vivo effect is a recurring theme in flavonoid pharmacology.
The practical implication is that while apigenin can inhibit aromatase in cell-based assays, it is not currently established that supplementing with apigenin produces a clinically meaningful reduction in estrogen synthesis in women. Anyone hoping to use apigenin as a substitute for pharmaceutical aromatase inhibitors should be aware that in vivo evidence for this effect is presently lacking [14].
Breast Cancer Context: Apigenin's Relationship with Hormone-Sensitive Cells
Because apigenin interacts with estrogen receptors, its behavior in hormone-sensitive cancer cells has been examined in several preclinical studies. A 2012 study found that apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors [4]. Medroxyprogesterone acetate is a synthetic progestin used in some hormone therapy regimens, and BT-474 is a HER2-positive, hormone receptor-positive cell line: the type that depends on hormone signaling to proliferate. The finding suggests apigenin may oppose hormone-driven tumor growth under at least some laboratory conditions.
The cell data are not one-directional: in MCF7 breast cancer cells apigenin stimulated growth at a low concentration (1 micromolar) and inhibited it at higher concentrations, and in mice it acted as a partial estrogen receptor agonist with estrogenic effects in estrogen-low conditions. These are not supplement doses [23][11].
A 2020 study examined apigenin’s effect on the full transcriptome of TNFα-activated MDA-MB-468 cells, a triple-negative breast cancer (TNBC) line lacking estrogen, progesterone, and HER2 receptors [7]. Apigenin modulated gene expression in this hormone-receptor-negative context, pointing to mechanisms beyond simple ERα binding. The 2026 dual PARP1/ESR1 inhibitor study [2] further positions apigenin as potentially relevant across multiple breast cancer subtypes through distinct molecular targets.
These are all preclinical findings. They do not establish that apigenin supplementation prevents or treats breast cancer in humans. Women with a personal or family history of hormone-receptor-positive breast cancer, or who are on anti-estrogen therapies, should discuss apigenin use with their oncologist before starting any supplement.
Fertility and Reproductive Considerations: Animal Data and Unanswered Questions
Apigenin’s reproductive profile is less well-characterized than that of isoflavones like genistein or daidzein. A 2025 study on bovine models examined how phytoestrogens modulate G protein-coupled receptors and regulate reproductive functions in animals [5]. The findings indicate that phytoestrogens can interact with hormone-signaling pathways involved in reproduction, including those relevant to follicular development and luteal function, in animal systems. This is mechanistically plausible given apigenin’s phytoestrogenic activity, but translating bovine reproductive data to human fertility is not straightforward.
No human clinical trials specifically examining apigenin’s effects on female fertility, ovulation, or menstrual cycle regularity have been identified in the current evidence base. The theoretical concern is that phytoestrogenic activity at supplemental doses could interfere with the precise hormonal signaling required for normal follicular development: a concern that has also been raised about high-dose isoflavone supplementation. Until human data exist, women who are actively trying to conceive should exercise caution with apigenin supplements above what is obtained from normal dietary intake and consult a reproductive endocrinologist or OB-GYN.
Drug Interactions and Safety for Women on Medications
In test-tube studies apigenin inhibited the cytochrome P450 enzymes CYP1A2, CYP2C9 and CYP3A4 [19][20][21]. These enzymes metabolize a wide range of medications that women in perimenopause and beyond commonly use. Warfarin is cleared through CYP2C9, and apigenin’s inhibition could theoretically elevate warfarin blood levels, increasing bleeding risk. Several statins use CYP3A4, as do some components of hormone therapy. Women on any of these medications should consult their prescribing physician before supplementing with apigenin.
Additionally, apigenin’s GABA-A receptor activity creates a potential for additive sedation when combined with benzodiazepines, prescription sleep medications, alcohol, or high-dose melatonin. For women in menopause who may already be using sleep aids to manage insomnia, a common symptom in this transition, this stacking risk is particularly relevant. In the chamomile clinical trial, two women in the chamomile group dropped out after mouth sores, skin spots and itching [3]. It used extract capsules rather than tea, so it says little about normal tea consumption, and concentrated apigenin supplements carry a different, untested risk profile [3].
Dietary Apigenin vs. Supplements: A Practical Distinction
A cup of chamomile tea typically delivers roughly 2 to 10 mg of apigenin depending on steeping time and brand, while commonly available apigenin supplements provide 50 to 100 mg or more per capsule. The clinical trial on chamomile for menopause symptoms [3] used a whole chamomile preparation, not isolated apigenin, meaning its reassuring safety data applies to the botanical, not necessarily to high-dose isolated compound. Survey data confirm that botanical supplement use in menopausal women is substantial [6], yet research directly comparing outcomes between tea, whole-herb preparations, and isolated high-dose apigenin in this population is lacking.
For most healthy women obtaining apigenin through food, the phytoestrogenic effects are likely modest and broadly consistent with long-term traditional use of chamomile and parsley-containing diets. The mechanistic concerns about estrogen receptor activity, potential reproductive hormone interactions, and CYP enzyme inhibition become more clinically meaningful at supplemental doses. This distinction is important when interpreting the preclinical research and deciding whether and how to use apigenin products.
🛒 Where to Buy Apigenin
- Momentous Apigenin
capsules, 50 mg per capsule, 60 count: NSF Certified for Sport, meaning batch testing against a banned-substance list and verification that the label matches the contents - Vitamatic Apigenin 50mg
capsules, 50 mg per capsule, 120 vegetarian capsules: The lowest cost per dose on this list, and a vegetarian capsule if gelatin is a constraint; the listing states no third-party certification - Nutricost Apigenin 50mg
capsules, 50 mg per capsule, 180 count: Non-GMO, gluten free and vegan, and the best cost per capsule among the larger bottles here - Swanson Apigenin 50mg
capsules, 50 mg per capsule, 90 count: A long-established supplement brand, in the smaller 90-count bottle; the listing frames it around sleep and relaxation
As an Amazon Associate we earn from qualifying purchases. Apigenin products differ mainly in what else is in the capsule (some are plain apigenin, others blend it with L-theanine, valerian root or magnesium) so check the label for the actual apigenin dose per serving, and prefer products that publish third-party testing.
A Note on the Evidence
The human clinical evidence on apigenin specifically for women’s hormonal health is limited; the most relevant human trial studied chamomile extract, not isolated apigenin, for menopausal symptoms [3], and most mechanistic findings come from cell cultures and animal models that may not translate directly to human physiology. Women who are pregnant, actively trying to conceive, undergoing cancer treatment, or taking medications metabolized by CYP1A2, CYP2C9, or CYP3A4 (including warfarin, certain statins, and oral hormonal medications) should consult a physician before using apigenin supplements.
Does Apigenin Lower Estrogen?
Apigenin does not simply “lower” estrogen, its documented activity is phytoestrogenic, meaning it can interact with estrogen receptors and, depending on context, act as a weak agonist or antagonist. Most of this evidence comes from cell and animal models rather than confirmed human hormonal outcomes. See the estrogen receptor activity section above for the mechanism-level detail.
Frequently Asked Questions
Does apigenin raise or lower estrogen levels in women?
Apigenin does not directly raise circulating estrogen in the way estrogen therapy would. It binds to estrogen receptors and may act as a weak phytoestrogen or SERM, potentially activating or modulating ER-dependent pathways depending on tissue context [1]. Whether this translates to measurable changes in women’s serum hormone levels at typical supplemental doses has not been established in human clinical trials.
Can apigenin help with hot flashes or other menopause symptoms?
A 2025 triple-blind clinical trial in 80 postmenopausal women found a larger fall in menopause symptom scores with a Matricaria chamomilla extract than with placebo over 12 weeks, though the placebo group also improved [3]. However, the extract contains numerous bioactive compounds beyond apigenin, so attributing the benefit specifically to apigenin would be premature. Dedicated human trials on isolated apigenin for menopause are needed before firm conclusions can be drawn [3].
Is apigenin safe for women with hormone-receptor-positive breast cancer?
This question requires an oncologist’s input, not a supplement label. Apigenin has shown inhibitory activity against ESR1 (estrogen receptor alpha) and hormone-sensitive cancer cell lines in laboratory studies [2][4], but these are preclinical findings that do not constitute clinical evidence of safety or efficacy. Its interactions with anti-estrogen therapies used in oncology are not well characterized in humans, making physician consultation non-negotiable.
Does apigenin affect fertility or the menstrual cycle?
Animal research shows that phytoestrogens, including apigenin-class compounds, can modulate reproductive hormone signaling pathways [5], but no human clinical trials examining apigenin’s effects on female fertility, ovulation, or menstrual regularity have been identified. The theoretical concern is interference with follicular development at higher supplemental doses. Women who are trying to conceive should discuss this with a reproductive specialist before supplementing.
Is it safe to drink chamomile tea daily for menopause support?
The 2025 clinical trial [3] used chamomile extract capsules, not tea, and two women in the chamomile group dropped out after mouth sores, skin spots and itching. The NCCIH describes chamomile as likely safe in tea amounts, and women on blood thinners, sedative medications or hormone therapy should check with their doctor first, because chamomile interactions with warfarin have been reported and apigenin inhibited CYP2C9 and CYP3A4 in test-tube studies [3][22][20].
Can apigenin interact with hormone therapy or hormonal contraceptives?
It is a possibility, not a demonstrated problem. Apigenin inhibited CYP3A4 and CYP2C9 in test-tube studies, and these enzymes are involved in metabolizing various hormonal medications, including certain oral contraceptives and hormone therapy components. The NCCIH notes that preliminary studies suggest chamomile could weaken birth control pills. Women on any hormonal medication should consult their prescribing physician before adding an apigenin supplement to their routine [21][20][22].
References
- Lecomte S et al. Assessment of the potential activity of major dietary compounds as selective estrogen receptor modulators in two distinct cell models for proliferation and differentiation. Toxicology and applied pharmacology (2017). PMID 28396216
- Arora M et al. Integrated in silico and in vitro evaluation of Genistein and Apigenin as dual inhibitors of PARP1 and ESR1 in breast cancer. BMC pharmacology & toxicology (2026). PMID 41495854
- Mohsenzadeh-Ledari F et al. Efficacy and safety of Matricaria chamomilla intervention in managing menopausal symptoms: a triple-blind clinical trial. Menopause (New York, N.Y.) (2025). PMID 39836709
- Mafuvadze B et al. Apigenin induces apoptosis and blocks growth of medroxyprogesterone acetate-dependent BT-474 xenograft tumors. Hormones & cancer (2012). PMID 22569706
- Safdar M et al. Phytoestrogens Modulate Bovine G Protein-Coupled Receptors and Play a Critical Role in Regulating Reproductive Functions in Animals. Reproduction in domestic animals = Zuchthygiene (2025). PMID 40116542
- Mahady GB et al. Botanical dietary supplement use in peri- and postmenopausal women. Menopause (New York, N.Y.) (2003). PMID 12544679
- Bauer D et al. Effect of apigenin on whole transcriptome profile of TNFα-activated MDA-MB-468 triple negative breast cancer cells. Oncology letters (2020). PMID 32194710
- Harris DM et al. Phytoestrogens induce differential estrogen receptor alpha- or Beta-mediated responses in transfected breast cancer cells. Experimental biology and medicine (Maywood, N.J.) (2005). PMID 16118406
- Kuiper GG et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology (1998). PMID 9751507
- Seo H et al. Receptor mediated biological activities of phytoestrogens. International journal of biological macromolecules (2024). PMID 39084415
- Yao L et al. Apigenin acts as a partial agonist action at estrogen receptors in vivo. European journal of pharmacology (2021). PMID 34048736
- Kellis JT Jr et al. Inhibition of human estrogen synthetase (aromatase) by flavones. Science (New York, N.Y.) (1984). PMID 6474163
- Sanderson JT et al. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicological sciences : an official journal of the Society of Toxicology (2004). PMID 15319488
- Saarinen N et al. No evidence for the in vivo activity of aromatase-inhibiting flavonoids. The Journal of steroid biochemistry and molecular biology (2001). PMID 11595503
- Campbell EL et al. The dietary flavonoids apigenin and (-)-epigallocatechin gallate enhance the positive modulation by diazepam of the activation by GABA of recombinant GABA(A) receptors. Biochemical pharmacology (2004). PMID 15451406
- Goutman JD et al. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. European journal of pharmacology (2003). PMID 12586201
- Salehi B et al. The Therapeutic Potential of Apigenin. International journal of molecular sciences (2019). PMID 30875872
- Zanoli P et al. Behavioral characterisation of the flavonoids apigenin and chrysin. Fitoterapia (2000). PMID 10930722
- Fei Lin et al. Inhibitory effect of Selaginella doederleinii hieron on human cytochrome P450. Frontiers in Pharmacology (2023). PMID 36874034
- Wang Z et al. Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro. Pharmacology (2016). PMID 27287328
- Kondža M et al. Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids. Molecules (Basel, Switzerland) (2021). PMID 34069400
- National Center for Complementary and Integrative Health (NIH) Chamomile: Usefulness and Safety. National Center for Complementary and Integrative Health (NIH) source
- Long X et al. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms. Molecular cancer therapeutics (2008). PMID 18645020
- European Medicines Agency (HMPC) European Union herbal monograph on Matricaria recutita L., flos (EMA/HMPC/55843/2011). European Medicines Agency (HMPC) (2015). source
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
